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In the last two years, clinical trials with blocking antibodies to the negative checkpoint
regulators CTLA-4 and PD-1 have rekindled the hope for cancer immunotherapy. Multiple
negative checkpoint regulators protect the host against autoimmune reactions but also
restrict the ability of T cells to effectively attack tumors. Releasing these brakes has
emerged as an exciting strategy for cancer treatment. Conversely, these pathways can
be manipulated to achieve durable tolerance for treatment of autoimmune diseases and
transplantation. In the future, treatment may involve combination therapy to target multi-
ple cell types and stages of the adaptive immune responses. In this review, we describe
the current knowledge on the recently discovered negative checkpoint regulators, future
targets for immunotherapy.
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introduction
T cells are initially stimulated through the T cell receptor (TCR) by the recognition of their cognate 
antigen presented by major histocompatibility complex (MHC) molecules. Optimal T cell activation 
requires a “second signal” provided by cosignaling molecules. Many of these molecules are members 
of the B7 family, and they act as rheostats that control the threshold for whether a given TCR interac-
tion leads to activation and/or anergy. Positive costimulatory signals promote T cell proliferation and 
acquisition of effector function. CD28 is one such molecule that facilitates fulminant T-cell activa-
tion upon recognition of its ligands CD80 and CD86 at the surface of mature antigen-presenting cell 
(APC). Negative checkpoint regulators (NCRs) are molecules that down-regulate immune responses 
to prevent out-of-proportion immune activation, minimize collateral damage, and maintain periph-
eral self-tolerance.
The two NCRs that have been most actively studied are cytotoxic T lymphocyte (CTL)-associated 
antigen 4 (CTLA-4, CD152) and programed cell death protein 1 (PD-1, CD279) (1). They regulate 
immune responses at very different levels and by very different mechanisms. CTLA-4 primarily 
regulates the amplitude of the early stages of T cell activation by both outcompeting CD28 in binding 
CD80 and CD86, as well as actively delivering inhibitory signals to the T cell. PD-1 predominantly 
regulates effector T cell activity within tissue and tumors where the immune response is ongoing. 
The FDA approval of the CTLA-4 blocking antibody, Ipilimumab (Bristol-Myers Squibb) in 2011 for 
the treatment of advanced melanoma, followed in September and December 2014 by the approval 
of two PD-1 blocking antibodies, Pembrolizumab (Merck) and Nivolumab (Bristol-Myers Squibb) 
mark the beginning of a new era for cancer immunotherapy.
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Multiple additional NCRs have been discovered in the recent 
years. The complex nature of the NCR pathways is only now 
being appreciated. These represent new promising targets for 
therapeutic manipulation.
TiM-3
The T-cell immunoglobulin and mucin-containing protein 3 
(TIM-3) was initially identified as a specific marker of fully 
differentiated IFN-γ producing CD4 T helper 1 (Th1) and 
CD8 cytotoxic (Tc1) cells (2). TIM-3 expression is regulated 
by T-bet, a Th1 transcription factor (3). In addition to T cells, 
TIM-3 is also highly expressed on regulatory T cells (Tregs), 
monocytes, macrophages, and dendritic cells (DCs). TIM-3 
shares a common structure with the other TIM family mem-
bers consisting of an N-terminal IgV domain followed by a 
mucin domain, a transmembrane domain, and a cytoplasmic 
tail. TIM-3 does not contain any known inhibitory signaling 
motifs but its phosphorylation on two intracellular tyrosine 
residues allows for the recruitment of the Src family tyrosine 
kinase Fyn and the p85 phosphatidylinositol 3-kinase (PI3K) 
adaptor (4).
The S-type lectin Galectin-9 (Gal-9) has been identified as one 
of TIM-3 ligands, binding the IgV domain of TIM-3 (5). Gal-9 is 
a widely expressed soluble molecule upregulated by IFN-γ (6).
TiM-3 Negatively Regulates Th1 and  
Tc1 Responses
Binding of Gal-9 to TIM-3 causes an inhibitory signal, resulting 
in apoptosis of Th1 cells and cytotoxic CD8 T cells in vitro (5, 7).
TIM-3/Gal-9 blockade generally induces hyperproliferation of 
effector cells associated with increased Th1 cytokine production 
(5) and increased CD8 T cell cytotoxicity (8). As a consequence, 
blocking TIM-3-mediated signaling on T cells in vivo accelerates 
or exacerbates Th1- and Tc1-mediated diseases. Gal-9 siRNA-
treated mice (5) and Gal-9 deficient hosts (9) present increased 
symptoms of experimental autoimmune encephalomyelitis 
(EAE), the mouse model of multiple sclerosis. In addition, both 
TIM-3 blocking antibody and TIM-3–Ig fusion protein exacerbate 
symptoms of EAE (5, 10, 11), type I diabetes in non-obese (NOD) 
mice (12), and acute graft-versus-host disease (aGVHD) (13, 14). 
Importantly, TIM-3 deficiency on donor T cells exacerbates EAE 
and aGVHD (10, 14). On the other hand, blocking this pathway 
can dampen allergen-induced airway inflammation by skewing 
the Th2 response toward a Th1 type (15).
Conversely, activating the TIM-3 pathway ameliorates various 
disease models. Gal-9 overexpressing mice are protected from 
aGVHD (14). Recombinant Gal-9 administration suppresses 
EAE (5, 9) and prolongs the survival of fully allogeneic skin or 
cardiac transplants (16–18). Gal-9 expressing islets are also pro-
tected from rejection by NOD T cells (19). In all these models, 
the protection conferred by Gal-9 is associated with a decrease in 
IFN-γ producing Th1 and/or Tc1 cells.
Taken together, these data strongly support the hypothesis that 
the upregulation of TIM-3 on activated T cells and its interaction 
with Gal-9 plays a critical role in attenuating and/or terminating 
both CD4 Th1 and CD8 Tc1 immune responses.
TiM-3 Regulates Th17/Tregs Differentiation
Whether and how TIM-3 and Gal-9 regulate Th17 cells is 
unresolved. While some studies show a negative effect of Gal-9 
on both Th1 and Th17 development in  vivo (16, 20), some 
studies show an impact on Th1 only (19). Gal-9 potentiates 
Treg conversion, and suppresses differentiation of Th17 cells 
in vitro (20, 21). As a result, Gal-9 administration ameliorates 
collagen-induced arthritis (CIA) by decreasing the levels 
of IFN-γ and IL-17 in the joints (20). However, one study 
demonstrated that Gal-9 suppression of Th17 development is 
TIM-3-independent (9).
In  vitro, blocking TIM-3 promotes both Th1 and Th17 
cytokine production by human and mouse CD4 T cells (8, 22). 
Similarly, in vivo TIM-3 blockade increases both Th1 and Th17 
cells (8). However, TIM-3 blockade does not increase incidence 
and severity of Th17-mediated EAE but alters the pattern of 
inflammation due to differential effects on Th1 versus Th17 cells 
(10). TIM-3 blockade also inhibits Treg differentiation in  vitro 
(8) and in vivo (12). As a result, TIM-3 deficient mice cannot be 
tolerized by high-dose aqueous antigen administration (11) and 
TIM-3 blockade abrogates Treg-mediated tolerance to allogeneic 
islets induced by donor-specific transfusion and costimulatory 
blockade (12).
Overall, evidence suggests that TIM-3 and Gal-9, possibly 
independently of each other, are involved in the differential 
regulation of Tregs and Th17 differentiation and contribute to T 
cell tolerance. One mechanism proposed is that TIM-3 negatively 
regulates IL-6 production by CD4 T cells. Therefore, blocking 
TIM-3 induces IL-6 production, which then antagonizes Treg 
differentiation and promotes IL-17 production by naive CD4 T 
cells (8).
TiM-3 Regulates innate Cell  
Activation/expansion
TIM-3 is highly expressed by innate immune cells including 
monocytes, macrophages, and DCs, and regulates their function 
in several ways.
In some circumstances, TIM-3 acts as a negative regulator of 
myeloid cell activation. Monney et al. first showed that a blocking 
TIM-3 antibody induces increased activation of macrophages (2). 
In addition, TIM-3 blockade during the innate immune phase of 
the response to coxsackievirus B3 (CVB3) infection exacerbates 
inflammatory heart diseases (23).
TIM-3 expression on macrophages can dampen TLR4-
mediated inflammatory reactions and damage (24). Moreover, 
expression of TIM-3 and TLR4 is reciprocally regulated (25, 
26). TIM-3 blockade enhances macrophage responsiveness to 
LPS stimulation, exacerbates sepsis (24), and enhances ischemia 
reperfusion injury damage in mouse liver transplantation 
(27). In these cases, the effect of TIM-3 blockade is depend-
ent on intact TLR4 expression. TIM-3 overexpression on 
macrophages as observed in chronic hepatitis C virus (HCV) 
infection, or by transgenic overexpression, is associated with 
diminished cytokine production upon stimulation (24, 26). 
However, TIM-3 overexpressing macrophages in hepatocel-
lular carcinoma patients promote tumor cell growth via IL-6 
production (28).
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On the other hand, several studies have indicated that TIM-3 
can promote activation and inflammatory cytokine production by 
innate immune cells. Triggering the TIM-3 pathway on DCs and 
monocytes via Gal-9 treatment or agonistic anti-TIM-3 antibody 
synergizes with TLR ligands to promote their activation (29). 
Gal-9 alone promotes the secretion of proinflammatory cytokines 
by TIM-3 expressing human and mouse monocytes and DC 
(30). In addition, Gal-9 treatment reverses immune suppression 
in tumor-bearing hosts and enhances survival by promoting the 
maturation of TIM-3 expressing DCs thus promoting adaptive 
immunity (31). These apparently contradictory results might be 
explained by a differential effect of TIM-3 on macrophages versus 
DCs. Other binding partners for TIM-3 and/or Gal-9 can also 
mediate this differential effect. In addition, the fact that TIM-3 
and Gal-9 can act as both receptors and ligands with regard to 
signaling has to be taken into account.
Several reports have indeed established that there is a 
reciprocal signal transmitted to the Gal-9 expressing innate 
immune cell. Therefore, a TIM-3–Ig fusion protein often used 
as a blocking reagent may trigger a signal to Gal-9 expressing 
cells independently of its blocking of TIM-3. For example, the 
interaction of Gal-9 expressed on macrophages with TIM-3 
expressed on Th1 enhances their bactericidal activity. This effect 
can be mimicked on macrophages by treatment with TIM-3–Ig 
(32, 33). Importantly, this effect is lost in Gal-9-deficient mac-
rophages (32). Kuchroo et  al. created TIM-3 Tg mice where 
TIM-3 overexpression is controlled by the human CD2 promoter 
and restricted to T cells. These mice display dampened T cell 
immunity resulting in increased tumor progression that is linked 
to the expansion of granulocytic myeloid-derived suppressor 
cells (MDSCs). Thus, TIM-3 expressed on T cells is sufficient to 
trigger a signal via Gal-9 in MDSCs and promote their expansion 
(34). In conclusion, both TIM-3 and Gal-9 are expressed and can 
signal in innate immune cells. Thus, cis and trans interactions 
might occur and the final effect results from the integration of all 
of these signals (35).
Additional Ligands and Partners for TiM-3 and 
Gal-9
As mentioned above, TIM-3 and Gal-9 may each have multiple 
binding partners. Several studies have found that Gal-9 may act 
through counter structures that are not TIM-3. First, Gal-9-
mediated cell death of Th1 cells is not completely abolished in 
TIM-3-deficient cells (5). In addition, Gal-9 induces proinflam-
matory cytokine production by T helper cells, suppresses Th17 
development, and induces plasma cell apoptosis in a TIM-3-
independent manner (9, 36, 37). A recent study also reported 
that TIM-3 does not act as a binding partner for Gal-9 on human 
T cells (38).
Early crystal structure studies of TIM-3 have revealed a Gal-9 
independent ligand-binding surface in the IgV domain (39) 
and several TIM-3 additional binding partners have since been 
uncovered. Like other members of the TIM family, TIM-3 also 
binds phosphatidylserine (PtdSer), exposed at the surface of 
apoptotic cells (40). Binding to PtdSer by TIM-3 mediates the 
uptake of apoptotic cells by TIM-3 expressing phagocytes such as 
CD8α DC and appears crucial for the clearance of apoptotic cells 
in vivo (41). TIM-3 blockade thus prevents uterine macrophages 
from clearing apoptotic cells and the resulting local inflammation 
increases fetal resorption (42).
TIM-3 also interacts with the high-mobility group protein B1 
(HMGB1). This interaction prevents the trafficking of nucleic 
acids into endosomes and decreases stimulation of endosomal 
TLR pathways thereby preventing tumor recognition by TIM-3 
expressing DCs and promoting tumor escape (43).
Finally, TIM-3 has recently been described to interact 
with the carcinoembryonic antigen cell adhesion molecule 1 
(CEACAM-1) in both cis and trans through their N-terminal 
domains. CEACAM-1 endows TIM-3-mediated inhibitory func-
tion by facilitating TIM-3 surface expression (44). In conclusion, 
TIM-3 and Gal-9 can both use multiple binding partners mediat-
ing various outcomes in both T cells and innate immune cells 
unraveling a very complex functional role.
TiM-3 Regulates T Cell exhaustion
TIM-3 expression has been described to mark the most dysfunc-
tional CD8 T cells in various chronic viral infections in both 
human and mice such as human immunodeficiency virus (HIV), 
HCV, and lymphocytic choriomeningitis virus (LCMV) (45–47). 
This state of T cell dysfunction, called T cell exhaustion, caused 
by chronic antigenic stimulation is characterized by the failure 
to respond further, proliferate, and exert effector functions such 
as cytotoxicity and cytokine secretion in response to antigen 
stimulation. These cells as discussed thereafter, often co-express 
other inhibitory molecules.
Similarly, TIM-3 and PD-1 are co-expressed on most CD4 and 
CD8 T cells infiltrating solid tumors or in hematologic malignancy 
in mice and these cells are dysfunctional (48, 49). TIM-3 and 
PD-1 expression is also upregulated on exhausted tumor-specific 
CD8 T cells in the blood of melanoma and lymphoma patients 
(50, 51). In both chronic viral infection and cancer, blocking 
TIM-3 ex vivo or in vivo increases the functionality of exhausted 
T cells and synergizes with PD-1 blockade to restore viral control 
(46, 52) or to inhibit tumor growth (48, 49).
TIM-3 expression on tumor-infiltrating lymphocytes (TILs) 
also defines highly suppressive Tregs in both human and mouse 
tumors (53–55). As a result, TIM-3 blockade and Treg depletion 
have a synergistic effect on tumor growth inhibition (54).
LAG-3
The lymphocyte-activated gene-3 (LAG-3, CD223) is a surface 
molecule highly homologous to CD4 in structure, but with 
less than 20% identity at the amino acid level (56). Like CD4, 
LAG-3 binds to MHC class II molecules, but with a much higher 
affinity (57).
LAG-3 is expressed on activated CD4 and CD8 T cells, and 
on activated Tregs (58) and Tr1 cells (59, 60). It is also expressed 
on a subset of NK cells (61) B cells (62) and plasmacytoid DCs 
(63). In resting T cells, LAG-3 is localized and degraded within 
the lysosomal compartments (64, 65). After stimulation, LAG-3 
is rapidly translocated to the cell surface where its expression 
is regulated by two TCR-induced metalloproteases, ADAM10 
and ADAM17. LAG-3 cleavage from the cell surface by these 
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metalloproteases allows for normal T-cell activation (66). 
As a result, LAG-3 is only transiently expressed at the surface 
of activated T cells stimulated in acute conditions, although it 
remains high on T cells stimulated within tolerizing environ-
ments (58, 67).
LAG-3 associates with the TCR:CD3 complex following TCR 
engagement and negatively regulates signal transduction (68). A 
single lysine residue (K468) within a conserved “KIEELE” motif 
in the cytoplasmic tail of LAG-3 is essential for interaction with 
downstream signaling molecules and inhibitory function (69).
LAG-3 Prevents Autoimmunity in Mice
LAG-3 deficiency alone does not induce autoimmunity in 
non-autoimmune-prone mouse strains (70–72) and does not 
induce major alterations in T cell development or function but 
a reduced NK cell cytotoxicity (70). Probably for that reason, 
LAG-3-deficient mice present a reduced ability to control tumor 
growth (72). However, LAG-3 blockade or LAG-3 deficiency 
accelerates diabetes in the predisposed NOD mice (71, 73). In 
addition, combined LAG-3 and PD-1 deficiency induces mas-
sive autoimmune conditions and early death in several different 
genetic backgrounds (71, 72). These clearly identify LAG-3 as a 
non-redundant negative T cell regulator.
LAG-3 Negatively Regulates T Cell Activation
Multiple evidences suggest that LAG-3 signaling directly inhibits 
primary activation of T cells in vitro and in vivo.
LAG-3 blockade induces increased proliferation and cytokine 
production by T cells activated in vitro (74, 75). In vivo, LAG-3-
deficient T cells exhibit a delay in cell cycle arrest resulting in a 
larger memory T cell pool following simian virus (SV) infection 
(76). LAG-3-deficient donor T cells also induce more severe 
aGVHD due to increased proliferation and enhanced effector 
functions (77).
LAG-3 also plays both a direct role and an indirect role in 
maintaining the tolerogenic state of CD8 T cells in vivo. LAG-3 
deficiency on CD8 T cells prevents the development of transgenic 
CD8 T cell tolerance, these cells are exposed to cognate self-Ag (78). 
In a different model of CD8 T cell tolerance induced by allogeneic 
bone marrow transplantation and costimulation blockade, LAG-3 
blockade also abrogates donor-specific CD8 T cell tolerance (79). 
However, in this system, LAG-3 is not intrinsically required on 
CD8 but must be expressed by other cells.
LAG-3 Regulates the induction and Suppressive 
Ability of Tregs and Tr1 Cells
LAG-3 is a marker of IL-10 producing Tr1 cells in both mice 
and humans (59, 60). Importantly, LAG-3 is one of the most 
overexpressed genes on CD4 transgenic T cells stimulated within 
a tolerizing environment (58, 78).
LAG-3 likely plays a crucial role in Tr1 induction and its 
function as ectopic LAG-3 expression in CD4 T cells confers 
a suppressive activity and blocking LAG-3 inhibits the sup-
pressive function of Tr1 cells in vitro and in vivo (58). LAG-3 
crosslinking on human T cells also induces a functional unre-
sponsiveness that can be reversed by IL-2, consistent with a Tr1 
phenotype (80).
LAG-3 is also highly expressed by activated natural Tregs 
(58). LAG-3 plays a role in modulating Treg induction/
expansion as LAG-3 deficiency on T cell or LAG-3 blockade 
prevents Treg conversion in favor of a TH1 skewing (81). 
The importance of LAG-3 for Treg-mediated suppression is 
controversial. In one study, LAG-3-deficient Tregs cannot 
suppress homeostatic proliferation (82), whereas two other 
studies showed no difference in LAG-3-deficient or -sufficient 
Tregs to suppress homeostatic proliferation and aGVHD (77, 
81). It is possible that LAG-3 is necessary for Treg-mediated 
suppression at high Effector/Treg ratios while being dispensa-
ble at lower ratios.
In these last two studies, LAG-3 expression on conventional 
T cells however, regulated their susceptibility to Treg-mediated 
suppression. LAG-3-deficient T cells undergo increased homeo-
static expansion when transferred in a lymphopenic host (82) 
and LAG-3 blockade also increases homeostatic expansion but 
only if Tregs are present (81). This involves a novel Treg-mediated 
suppression mechanism following MHC class II acquisition by 
Tregs through trogocytosis and subsequent inhibition of LAG-3 
expressing conventional T cells (77). Thus, LAG-3 appears as a 
crucial molecule involved in both the development and function 
of suppressive T cells.
LAG-3 Regulates innate Cell Activation
Similar to other NCRs, LAG-3 is bidirectional in its signaling 
capacity and modulates DC activation by inducing downstream 
signaling via MHC class II molecules. LAG-3 expressed on 
activated T cells induces DC maturation with the production of 
TNFα and IL-12 in vitro. As a result, LAG-3 blockade in DC:T 
cell cocultures, prevents DC activation, and inhibits rather than 
increases T cell proliferation (83). This T-cell-mediated effect on 
DC can be mimicked by soluble LAG-3-Ig fusion protein (84). As 
a result, LAG-3–Ig acts as an adjuvant increasing Th1 and cyto-
toxic T cell responses to soluble antigen in vivo (85). Similarly, 
LAG-3–Ig administered together with irradiated tumor cells 
induces tumor regression and increases tumor cell-specific CD8 
T cell responses (86). However, during Treg:DC interactions, 
LAG-3 engagement with MHC class II inhibits DC activation. 
In this case again, LAG-3-mediated signaling is not required but 
its binding to MHC II molecules initiates an inhibitory signaling 
pathway that suppress DC maturation (87). MHC II engagement 
through LAG-3 or crosslinking induces several pathways that 
have to be finely regulated to lead to cell activation or inhibition 
(88). Additional signals differentially expressed by activated T 
cells and Tregs such as CD40L might also influence the outcome 
of this interaction (83).
Additional LAG-3 Ligands
As for other NCRs, two other binding partners for LAG-3 have 
been described which are expressed in the tumor microenvi-
ronment: the Liver sinusoidal endothelial cell lectin (LSECtin) 
and Galectin-3 (Gal-3). Engagement of LAG-3 by LSECtin 
expressed in melanoma cells inhibits IFNγ production by 
effector T cells and increases IL-10 production by Tregs (89). 
Gal-3, a galactoside-binding soluble lectin is expressed in sev-
eral cell types and involved in a broad range of physiological 
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and pathological processes. Gal-3 binds to LAG-3, and LAG-3 
expression is necessary for Gal-3-mediated suppression of 
tumor-specific CD8 T cells. Gal-3 deficiency on both T cells 
and the host improves tumor-specific CD8 T cell response 
suggesting both cis and trans interactions between the two 
molecules (90).
LAG-3 Regulates T Cell exhaustion in Cancer 
and Chronic infections
In addition to PD-1 and TIM-3, LAG-3 is also upregulated and 
maintained in exhausted T cells in both chronic viral infections 
and cancer. LAG-3 is upregulated on virus-specific CD8 T cells in 
chronic LCMV infection. A functional role of LAG-3 in exhaus-
tion is suggested by the fact that LAG-3 blockade synergized with 
PD-1 blockade to reverse exhaustion and improve viral control 
(91). LAG-3 expression on HIV-specific CD4 and CD8 T cells 
is also correlated with disease progression. Interestingly in HIV 
patients, LAG-3 and PD-1 are expressed on distinct subsets of 
exhausted T cells (92). LAG-3 and PD-1 are co-expressed on TILs 
in ovarian and on tumor-specific CD8 T cells in the blood of ovar-
ian cancer patients (93). LAG-3 and PD-1 are also co-expressed 
on CD4 and CD8 TILs in various mouse tumor models (72). 
LAG-3 blockade alone does not always reverse the exhausted 
phenotype but can synergize with PD-1 blockade to improve 
effector functions and control viral load (91, 92) or induce tumor 
regression (72, 93).
TiGiT
The T cell immunoreceptor with Ig and ITIM domains (TIGIT/
Vstm3/WUCAM/VSIG9) is a novel member of the immuno-
globulin super family (IgSF). TIGIT was recently identified by 
two independent groups through a genomic search for genes 
specifically expressed in T cells and bearing a structure similar to 
other immunomodulatory receptors (94, 95). TIGIT is a type 1 
transmembrane protein containing an IgV extracellular domain 
and an immunoglobulin tail tyrosine (ITT)-like phosphorylation 
motif followed by an immunoreceptor tyrosine-based inhibitory 
motif (ITIM) in the cytoplasmic tail.
TIGIT pairs with CD226/DNAM-1 (DNAX Accessory 
Molecule-1) to form an emerging pathway that has striking 
similarities to the CTLA-4/CD28 pathway. CD226 and TIGIT 
bind the same set of ligands, the two nectin-family members 
poliovirus receptor (PVR) (CD155/Necl-5/Tage4) and poliovirus 
receptor-related 2 PVRL2 (CD112), and compete with each other 
(96). Both ligands are members of the nectin-like family, are 
widely expressed outside the hematopoietic system on fibroblasts 
and endothelial cells, and are involved in cell adhesion and motil-
ity. Notably, PVR is overexpressed in several tumor cells types (97, 
98) and can be induced by Ras activation and genotoxic stress (99, 
100). PVR is also induced by TLR ligand-activated APCs (101). 
Whereas CD226 is widely expressed on most immune cells (102), 
TIGIT is absent on naive T cells, but is expressed on activated and 
memory T cells, Tregs (94) and on NK cells and NKT cells (95) in 
mice and humans. Human TIGIT engagement by PVR induces a 
tyrosine phosphorylation on the ITT domain. This results in the 
recruitment of the phosphatase SHIP1 through different cytosolic 
adaptors leading to inhibition of phosphatidylinositol 3-kinase 
(PI3K), MAPK, and NF-kB signaling (103, 104). In mice, phos-
phorylation of either the ITT or the ITIM domain is sufficient for 
TIGIT-mediated inhibition (105).
CD226 Costimulates NK and T Cell Responses
PVR recognition by CD226 potentiates CD8 T cell and NK cell 
cytotoxicity toward tumor cells (97, 106, 107). Notably, CD226 is 
a crucial costimulatory molecule for CD8 T cells when activated 
by non-professional APC such as B cells but is dispensable when 
T cells are activated by professional APCs (108). As a result, 
CD226-deficient mice have impaired anti-tumor and antiviral T 
cell responses (109, 110). Upon engagement, CD226 is phospho-
rylated and interacts with LFA-1 inducing their recruitment to 
lipid rafts (111–114). CD226 deficiency thus impairs immuno-
logical synapse formation between CD8 T cells and target cells 
preventing the deliverance of the cytotoxic payload necessary 
for target cell killing (115). CD226 also regulates CD4 T cell 
expansion and cytokine production. CD226 blockade decreases 
Th1 differentiation and suppresses EAE while PVR deficiency 
decreases Th2 polarization (101, 102).
The polymorphism variant Gly306Ser of CD226 has been 
associated with susceptibility to multiple autoimmune diseases 
such as SLE, autoimmune thyroid disease, Type 1 diabetes, MS, 
and Celiac disease (116, 117).
TiGiT Has T-Cell-intrinsic inhibitory Function
Several reports attest that TIGIT negatively regulates T cell 
activation. While TIGIT deficiency alone does not induce overt 
autoimmunity, TIGIT pathway blockade exacerbates several 
immune diseases. TIGIT-deficient mice are more susceptible to 
EAE (118) and blocking TIGIT results in more rapid CIA and 
EAE diseases onset (96). TIGIT deficiency also induces neuro-
logical dysfunction in EAE susceptible, myelin oligodendrocyte 
glycoprotein (MOG)-specific TCR transgenic 2D2 mice (118). 
Finally, TIGIT-deficient T cells induce more severe GVHD (96).
Conversely, increased TIGIT function on T cells has been 
shown to ameliorate a variety of autoimmune disease models 
in mice. Soluble TIGIT decreases CIA and mice overexpressing 
TIGIT in T and B cells are protected against EAE (96). Lentiviral 
overexpression of TIGIT in CD4 T cells decreases their ability to 
mediate bone marrow damage and lengthens survival time in a 
mouse model of aplastic anemia (119).
The mechanism of TIGIT-mediated T cell inhibition is 
unclear. Some evidences suggest that TIGIT can directly inhibit 
T cell activation. In vitro, TIGIT engagement by an agonistic anti-
body decreases both human and mouse T cell activation when 
stimulated with anti-CD3 and anti-CD28 (119, 120). Conversely, 
TIGIT knockdown increases T cell proliferation and effector 
cytokine production while decreasing IL-10 production (119). 
This suggests that the negative downstream signaling via TIGIT 
could arrest T cell activation. However, TIGIT can also indirectly 
inhibit T cell activation by opposing the CD226-mediated posi-
tive costimulatory signal either through ligand competition or 
CD226 inhibition. As evidence, when T cells are activated with 
PVR transfected artificial APCs, a blocking TIGIT antibody 
increases T cell proliferation while soluble TIGIT-Ig decreases 
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it (96). TIGIT deficiency or blockade also increases T cell prolif-
eration to anti-CD3 and PVR-Ig stimulation. Importantly, when 
T cells are activated in the presence of PVR, TIGIT-mediated 
inhibition seems dependent on CD226, as CD226 blockade 
annihilates the positive impact of TIGIT blockade (121). FRET 
studies indicate that TIGIT and CD226 directly interact at the cell 
surface and that this interaction impairs CD226 homodimeriza-
tion and function (121).
TiGiT Regulates DC immunostimulatory 
Function
As mentioned before, most immunoregulatory molecules func-
tion in a bidirectional way and TIGIT also induces a reciprocal 
signal in PVR expressing APC. PVR engagement on DC with 
TIGIT-Ig induces IL-10 while suppressing pro-inflammatory 
cytokines production such as IL-12. Upon TIGIT ligation, PVR is 
phosphorylated and elicits downstream signaling in DCs, which 
then inhibits T cell responses by producing IL-10. In addition, 
TIGIT blockade exacerbates T cell responses only in the presence 
of DC. Finally, TIGIT–Ig-mediated inhibition of delayed type 
hypersensitivity (DTH) reactions in vivo is dependent of IL-10 
(94). All these suggest that TIGIT negative regulation of T cell is 
indirect and mediated at least in part through modification of the 
immunostimulatory function of APCs.
In addition, TIGIT also exerts a direct inhibitory role on APCs 
as TIGIT-deficient APCs are better at promoting T cell prolifera-
tion. The maximal APC-induced T cell proliferation is achieved 
by combining both deficient T cells and deficient APCs suggest-
ing that TIGIT has synergistic roles on T cells and APCs (118).
TiGiT Negatively Regulates NK Cell effector 
Function
In addition to T cell inhibition, TIGIT negatively regulates NK cell 
cytotoxicity and cytokine production. TIGIT blockade increases 
NK cell cytotoxicity toward PVR expressing targets. Interestingly, 
TIGIT inhibition is dominant over the coactivation mediated by 
CD226 on NK cells (95, 105) whereas the net effect of PVR-T-
cell interaction appears costimulatory (96). This might be due to 
additional inhibitory mechanisms preventing NK cytotoxicity. 
Indeed, NK cells also express CD96, another inhibitory recep-
tor that also competes with CD226 for PVR binding (122). In 
addition, only co-blockade of TIGIT and MHC class I increases 
NK-mediated cytotoxicity against fibroblasts. TIGIT may thus 
represent an “alternative self ” mechanism for MHC class I inhi-
bition, preventing damage to self-tissue (95). Using mutants of 
TIGIT transfected into a YTS NK cell line and PVR transfected 
7721.221 target cells, Fan et  al. deciphered the mechanisms 
involved in TIGIT-mediated inhibition of NK cells. In these cells, 
direct TIGIT-mediated negative downstream signaling results in 
impaired granule polarization (104) and IFN-γ production (103).
TiGiT Promotes Treg Differentiation and Defines 
Activated, Highly Suppressive Tregs
TIGIT transcription is directly regulated by FoxP3 (123). TIGIT 
promotes inducible Treg differentiation as TIGIT deficiency 
decreases Treg conversion in vitro. Conversely, T cells overexpress-
ing TIGIT generate greater frequencies of Tregs (124). In vivo, 
TIGIT expression defines a subset of activated natural Tregs with 
superior suppressive capacity in both humans and mice (125). 
TIGIT-expressing Tregs express higher amount of PD-1, CTLA-4, 
LAG-3, and TIM-3 and produce more IL-10 and Fibrinogen-like 
protein 2 (Fgl2). Notably, Fgl2 production is induced by TIGIT 
engagement and is responsible for the increased suppressive 
ability of TIGIT Tregs. These Tregs specifically suppress Th1 
and Th17 responses in vivo, while promoting Th2 responses in 
an Fgl2-dependent manner (124). In human, co-expression of 
TIGIT and Fc receptor-like protein 3 (FCRL3) identifies Helios + 
memory Tregs (125, 126). Thus, as other NCRs, TIGIT is critically 
involved in Treg development and suppressive function.
TiGiT Regulates T Cell exhaustion
Similar to PD-1, TIM-3, and LAG-3, TIGIT is upregulated on 
exhausted T cells in both chronic viral infections and cancer 
(121). A gene signature-based approach identified TIGIT expres-
sion as a marker for tumor-associated T cells. The TIGIT:CD3 
ratio is increased on T cells in multiple human tumors compared 
to the corresponding normal tissues indicating that TIGIT is 
specifically upregulated in tumor-infiltrating T cells. Indeed, 
TIGIT is highly expressed on CD8 T cells co-expressing PD-1 
infiltrating non-small cell lung carcinoma (NSCLC) and colo-
rectal carcinoma (CRC) as well as several mouse tumor models. 
TIGIT is also elevated on CD4 and CD8 T cells in the blood of 
cancer patients. Whereas PD-L1 or TIGIT blockade alone have 
little effect, PD-L1 and TIGIT co-blockade dramatically improves 
CD8-mediated control of tumor growth leading to complete 
rejection in the majority of mice. Importantly only PD-L1 and 
TIGIT co-blockade elicit IFNγ and TNFα production by CD8 
TILs (121).
In mice chronically infected with the Clone 13 strain of LCMV, 
TIGIT is highly expressed by PD-1high exhausted T cells and 
TIGIT blockade acts synergically with PD-1 blockade to improve 
CD8 T cell effector function and viral control. TIGIT conditional 
knock down in T cells also improves antiviral T cell response and 
viral control. However, as mentioned above, TIGIT inhibition of 
T cells seems mediated by CD226 disruption as CD226 blockade 
annihilates the curative impact of TIGIT and PD-L1 co-blockade 
on both tumor growth and chronic infection (121). Interestingly, 
CD226 expression is downregulated on virus-specific CD8 T 
cells in both human HIV and mouse LCMV chronic infection 
reinforcing the proposition that the costimulatory pathway medi-
ated by CD226 is disrupted in chronically exhausted T cells (127).
BTLA
B and T lymphocyte attenuator (BTLA) was identified as another 
NCR in the IgSF structurally related to CTLA-4 and PD-1 (128, 
129). BTLA expression is limited to lymphoid tissues, with 
highest expression on B cells, but also significant on both αβ 
and γδ T cells, mature DCs, and macrophages (128, 129). BTLA 
is expressed on naïve T cells, transiently upregulated upon 
TCR engagement, but is down regulated on fully activated T 
cells. However, in similarity with LAG-3, BTLA remains high 
on T cells rendered anergic in  vivo (130). Its absence on fully 
activated T cells distinguishes it from other B7 family members 
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like PD-1 and CTLA-4 (130,  131). Unique for a IgSF member 
protein, is the counter-receptor that BTLA binds. BTLA binds to 
the herpesvirus entry mediator (HVEM), which is a member of 
the tumor necrosis factor receptor superfamily (TNFRSF) (132, 
133). HVEM is expressed on T cells, B cells, NK cells, DCs, and 
myeloid cells (133). HVEM was originally described as a receptor 
for HSV glycoprotein D, but interacts with multiple other ligands 
in addition to BTLA, including CD160 and LIGHT. CD160 is 
another negative receptor on T cells (134), while LIGHT is a 
costimulatory molecule. Crosstalk across protein families and the 
use of multiple binding partners by each protein are indicative of 
the widespread complexity of the system of negative checkpoint 
regulation. Like PD-1 and CTLA-4, BTLA contains two conserved 
ITIMs in its cytoplasmic tail (129). BTLA engagement is associ-
ated with phosphorylation at those two ITIMs motifs resulting in 
the association of the Src homology domain 2 (SH2)-containing 
protein tyrosine phosphatases SHP-1 and SHP-2 (128, 129, 135) 
with either the TCR or the BCR.
BTLA Negatively Regulates T Cell Activation
In vitro studies demonstrate a direct negative activity of BTLA on 
T cell proliferation and cytokine production. BTLA-deficient T 
and B cells show enhanced proliferation in response to anti-CD3 
and anti-IgM respectively (128, 129). Retroviral overexpression 
of BTLA in DO11.10 cells or agonist BTLA antibody suppresses 
anti-CD3-induced IL-2 production (129, 135). In addition, 
HVEM–Fc fusion protein inhibits T cell proliferation in 
response to multiple agonists (132). Interestingly, BTLA signal-
ing induced by agonist antibody can act on T cell proliferation as 
far as 16 hours after TCR engagement, suggesting that the criti-
cal point of impact is during the later, more stable T cell–APC 
interactions (135).
BTLA Regulates Peripheral Tolerance
BTLA deficient mice gradually develop elevated anti-self anti-
bodies, an increased number of activated CD4 T cells in the 
periphery and inflammatory cell infiltration of multiple organs. 
This can progress to development of a hepatitis-like disease and 
overall reduced survival (136). Consistent with this breakdown 
in peripheral tolerance, BTLA-deficient mice are resistant to 
the induction of T cell tolerance to an oral antigen or to high-
dose antigen administration (137). In addition, BTLA-deficient 
ovalbumin-specific OT-I CD8 T cells cannot be tolerized by 
encounter with their cognate antigen in vivo and cause diabetes 
in RIP-mOVA recipient mice (137). BTLA-deficient mice also 
present increased susceptibility to EAE (129) and mice deficient 
in either BTLA or HVEM present heightened T cell and NKT cell 
responses to Con A and exhibit increased morbidity and mortal-
ity to Con A-mediated T cell-dependent autoimmune hepatitis 
(138, 139). Conversely, BTLA engagement leads to the induc-
tion of tolerance. An agonistic BTLA antibody prolongs heart 
allograft survival by suppressing alloreactive T cell responses and 
inducing IL-10-producing Tregs (140). In addition, a single dose 
of agonist BTLA antibody prevents the development of GVHD if 
given at the time of transplantation (141). In these models, BTLA 
engagement seems to favor the expansion of Tregs over T effector 
cells, adjusting the balance toward tolerance.
BTLA Regulates innate immunity
More recent studies have shown that BTLA is also able to 
regulate multiple lineages of cells within the innate immune 
system. BTLA-deficient mice on the RAG-deficient background 
are less susceptible to Listeria Monocytogenes infection (142). 
The authors reported that the loss of BTLA in the CD8α  DC 
compartment prevents Listeria expansion within these cells. It is 
known that CD8α + DCs are necessary for Listeria expansion 
and dissemination within the host. In wild-type mice, BTLA 
normally suppresses Fas/FasL signaling in DCs to allow high 
levels of Listeria to grow and thereby induce potent protective 
CD4 and CD8 responses. In BTLA-deficient DCs, where Fas/FasL 
is enhanced, Listeria burden is reduced as is the adaptive immune 
response keeping it in check. Therefore, BTLA can exert direct 
immunoregulatory effects within the DC compartment.
Possessing both a rearranged specific TCR and rapid innate 
functions, γδ T cells are poised between the innate and adaptive 
arms of the immune response. BTLA appears to play a major role 
in both their homeostasis and function. The pool of γδ T cells is 
maintained through competition for survival signals from IL-7 or 
IL-15. In γδ T cells, IL-7 increases BTLA levels on the cell surface, 
which in turn, restricts their expansion and negatively regulates 
IL-17 and TNFα. BTLA-deficient mice thus exhibit enhanced 
disease in a γδ T cell-dependent model of dermatitis whereas an 
agonistic BTLA antibody reduces inflammation (143).
A particular role for BTLA has been described for Vγ9Vδ2 T 
cells. This subset is thought to have functions in tumor immune 
surveillance. In human Vγ9Vδ2 T cells, BTLA interaction with 
HVEM–Fc fusion protein negatively regulates Vγ9Vδ2 T-cell 
proliferation to both TCR-dependent and -independent activa-
tion. During TCR-mediated activation, BTLA clusters to the TCR 
and decreases phosphorylation of ZAP-70 and Erk1/2. BTLA 
blockade increases TCR signaling and restores the ability of 
human Vγ9Vδ2 T cells to react to HVEM expressing lymphoma 
cells (144). Although these suppressive activities show similarity 
to PD-1 and CTLA-4, the primarily naïve and central memory 
expression of BTLA distinguishes it from these immunoregula-
tors, and gives BTLA its own niche.
In a transfer model of colitis, HVEM expressed on a radioresist-
ant cell population interacting with BTLA was found to be critical 
in preventing inflammation (145). Surprisingly, BTLA expression 
on the donor T cells had a minor impact, and BTLA expression 
was more important in the recipient RAG-deficient mice. These 
data suggest that these molecules should be examined outside of 
the usual T cell–APC focus.
BTLA as a Ligand Demonstrates T Cell  
Pro-Survival Function
A wealth of reports demonstrates a negative receptor function for 
BTLA. However, like many of the immunoregulatory molecules 
that can act as both receptors and ligands, BTLA also appears 
to induce a reciprocal positive pro-survival signal in HVEM-
expressing T cells. Indeed, BTLA has been implicated in sustain-
ing the survival of HVEM-expressing effector and memory T 
cells in various mouse models (145–147). Particularly, during 
vaccinia virus infection, HVEM expression on T cells and BTLA 
expression on the host are both necessary for the development of 
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a protective response. In this model, BTLA expressed by APCs 
functions as a ligand that delivers positive signals in trans to 
HVEM expressing T cells (147).
An important point is that T cells express both HVEM and 
BTLA and several reports also demonstrate that BTLA expression 
by T cells is also critical for their survival. In a GVHD model, 
transfer of BTLA-deficient donor cells results in an impaired 
anti-host response due to a loss in donor T cell survival (148). 
Similarly, BTLA-deficient T cells do not induce increased colitis 
when transferred into RAG-deficient mice because of an impaired 
accumulation (145). A positive correlation has also been described 
between BTLA expression and the ability of human T cells to 
generate recall responses to the Mycobacterium tuberculosis 
antigen Ag85B (149). Sakoda et al. confirmed these findings and 
showed that expression of the extracellular domain of BTLA is 
sufficient to restore the survival of BTLA-deficient T cells during 
GVHD, further demonstrating the role of BTLA on T cells as a 
ligand in this model (150). BTLA-deficient T cell survival is also 
rescued with BTLA–Fc fusion protein (150, 151). Cellular BTLA 
and BTLA–Fc induce the recruitment of TNF receptor-associated 
factor 2 (TRAF2) to HVEM, promoting NF-κB activation and cell 
survival (151). Importantly, BTLA function as a ligand to induce 
pro-survival signal in GVHD is associated with its expression on 
donor T cells but not on recipient cells (150). A BTLA–HVEM 
interaction in cis on T cell could explain these findings. However, 
one report demonstrates that HVEM–BTLA cis interaction com-
petitively inhibits HVEM activation by ligands expressed in the 
surrounding microenvironment rather suggesting a bystander 
T:T trans interaction involved in the BTLA–HVEM-mediated 
survival effect (152).
BTLA Negatively Regulates Tumor immunity
HVEM is expressed in 26 of 40 melanoma cell lines and 
moderately to strongly expressed on 75% of human mela-
noma metastases (153). BTLA and PD-1 are co-expressed on 
tumor-specific CD8 T cells in melanoma patients (153, 154) 
and these cells are dysfunctional (154). However, contrary to 
PD-1, BTLA upregulation seems to occur independently of 
the functional exhaustion driven by high antigen load (154). 
BTLA can be downregulated by vaccination with peptide and 
CpG oligodeoxynucleotides with a resulting loss of sensitivity 
to HVEM-mediated suppression of cytokine production (153). 
Importantly, BTLA blockade synergizes with PD-1 and TIM-3 
blockade in enhancing proliferation and cytokine production 
by tumor-specific T cells in  vitro indicating a non-redundant 
role for BTLA (154). Similarly, BTLA blockade combined with 
active immunization enhanced anti-tumor immunity (155) 
and can lead to regression of large adenocarcinomas in mice 
(156). However, as discussed above, the effect of BTLA may not 
be completely negative. BTLA expressing TILs appear more 
proliferative to IL-2. This may be because BTLA expression is 
higher on newer central memory type cells that are less likely to 
be exhausted. In addition, BTLA positive cells present reduced 
sensitivity to activation-induced cell death. These data indicate 
that BTLA may extend the life of TILs, but also maintain qui-
escence (157).
viSTA
The V-domain Ig suppressor of T cell activation (VISTA) also 
known as PD-1 homolog (PD-1H) has recently been identified by 
our group and others as a novel NCR in the IgSF. VISTA is a type 
I transmembrane protein with a single IgV domain with sequence 
homology to the IgV domains of the members of CD28 and B7 
families (158, 159). VISTA cytoplasmic tail domain contains two 
potential protein kinase C binding sites as well as proline residues 
that could function as docking sites, suggesting that VISTA could 
potentially function as both a receptor and a ligand. VISTA does 
not contain ITIM-like motifs. Modeling algorithms have sug-
gested homology to either PD-1 (158) or PD-L1 (159). The counter 
structures interacting with VISTA have not been identified yet.
Unlike PD-L1, VISTA expression is restricted to the hemat-
opoietic compartment. It is constitutively and highly expressed 
on CD11b myeloid cells such as neutrophils, monocytes, mac-
rophages, and DCs, and expressed at lower levels on naïve CD4 and 
CD8 T cells and Tregs both in humans (160) and mice (158, 159).
viSTA Regulates Peripheral Tolerance
The negative regulatory function of VISTA is clearly demon-
strated in deficient mice. VISTA-deficient mice demonstrate 
an age-related proinflammatory signature, with elevated serum 
cytokines, spontaneous T cell activation, and chronic multi-
organ inflammation. Nonetheless, single VISTA deficiency as 
well as VISTA/PD-1 and VISTA/PD-L1 double deficiencies do 
not induce overt autoimmunity in the absence of other predispos-
ing factors (161–163).
However, VISTA deficiency on the 2D2 transgenic EAE 
susceptible background dramatically increases disease inci-
dence and severity with 60% of mice dying by 2–3 months of 
age (163). Combined deficiency of VISTA and PD-1 further 
increases disease penetrance to 90% (162). On a non-susceptible 
background, VISTA blockade also accelerates EAE onset and 
severity (159).
VISTA appears to function both as a negative receptor on 
T cells and as a ligand expressed on APCs interacting with an 
unknown receptor on T cells. As evidenced, in a passive transfer 
model of EAE, VISTA deficiency on both T cells and host con-
tribute to the control of autoimmunity with the most aggressive 
disease obtained by transferring VISTA-deficient pathogenic 
T cells into VISTA-deficient hosts. VISTA expression on the 
host, however, appears to contribute more than that on T cells 
as VISTA-deficient hosts always present accelerated disease 
regardless of the status of the T cells transferred (163). In vitro, 
maximal antigen-specific proliferation is achieved when both 
APCs and T cells are deficient, again supporting that VISTA 
on both T cells and APCs contributes to the inhibition of T cell 
proliferation via specific pathways (161).
viSTA as a Ligand Negatively Regulates T Cell 
Activation
Several findings suggest that VISTA negatively regulates T cell 
responses by acting as a ligand that interacts with an unknown 
receptor on T cells. A soluble VISTA–Ig fusion protein inhibits 
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human and mouse CD4 T cell proliferation and cytokine produc-
tion in vitro by suppressing early TCR activation (159, 160). A 
single dose of VISTA–Ig fusion protein prevents the development 
of GVHD in mice if given at the time of transplantation (158). 
When expressed on APCs, VISTA decreases antigen-specific T 
cell proliferation. VISTA blockade thus increases proliferation 
when T cells are stimulated with VISTA expressing myeloid APCs. 
Moreover, ectopic expression of VISTA on tumor cells interferes 
with protective anti-tumor immunity and allows increased tumor 
growth in vaccinated hosts (159).
viSTA as a Receptor Negatively Regulates T Cell 
Activation
Several findings also suggest a direct negative role of VISTA 
as a receptor on T cells. VISTA-deficient T cells respond by 
increased antigen-specific proliferation and cytokine production 
when compared to WT T cells in vitro and in vivo. On the other 
hand, VISTA engagement by an agonistic antibody suppresses 
antigen-specific proliferation when T cells are activated by 
VISTA-deficient APCs (161). In this system, because the APCs 
are deficient, VISTA on T cells functions independently of APCs 
to suppress T cell responses.
As a receptor on T cells, VISTA seems critical for the regula-
tion of allogeneic responses. While an agonistic anti-VISTA 
antibody potently suppresses GVHD in mice (158), it does not 
prevent GVHD induced by VISTA-deficient donor T cells (164). 
In addition, VISTA-deficient T cells induce exacerbated GVHD 
with increased donor T cell expansion and decreased survival. 
However, VISTA-deficient recipient do not present aggravated 
GVHD, indicating that VISTA expression on recipient cells 
(APC) had little effect on the regulation of allogeneic T cells in 
this disease model (164).
viSTA Regulates Treg Differentiation and 
Suppressive Function
VISTA is also highly expressed by a subset of Tregs and like most 
NCRs seems to contribute to their differentiation and suppres-
sive function. VISTA–Ig fusion protein promotes the induction 
of both human and murine Tregs in vitro (160, 165) and VISTA 
blockade decreases the generation of tumor-specific Tregs in vivo 
(165). This suggests that as a ligand, VISTA can promote Treg 
generation.
Some evidence suggests that VISTA may also be involved in the 
suppressive function of Tregs. First, VISTA expression is highly 
upregulated on tumor-infiltrating Tregs, indicating that VISTA on 
Tregs could play a role in suppressing tumor-specific immunity. 
In addition, VISTA blockade can reverse Treg-mediated suppres-
sion in vitro. However, VISTA blockade reverses suppression by 
both low VISTA expressing Tregs and high VISTA expressing 
Tregs and also increases the proliferation of T cells in the absence 
of Tregs, indicating that it might not be directly involved in Treg-
mediated suppression. In this system, VISTA could function both 
as a receptor on T cells and a ligand expressed by Tregs (165).
viSTA Regulates Myeloid Cell Activation
As mentioned, VISTA is highly expressed by myeloid cells. Its 
expression can be further upregulated on human monocytes by 
TLR ligands as well as IL-10 and IFNγ. Overexpression of VISTA 
is observed in monocytes from chronically HIV-infected patients. 
Heightened VISTA expression correlates with immune activation 
and CD4 depletion (166). Enforced VISTA overexpression on 
human monocytes/macrophages induces spontaneous secretion 
of multiple inflammatory cytokines at levels similar to fully 
activated monocytes. The process requires signaling via VISTA 
as cytokine secretion is abrogated by deletion of the cytoplasmic 
FiGURe 1 | Summary of NCRs expression on  immune cell populations and their functions.
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domain of VISTA. Interestingly, VISTA overexpression on HIV 
patients’ monocytes also enhances their ability to stimulate 
IFNγ production by HIV-specific T cells. Furthermore, VISTA 
inactivation decreases the antigen presentation ability. In this 
pathological situation, VISTA positive regulation of myeloid cells 
seems to overcome the negative signal to T cells (166). Thus, in 
addition to acting as a ligand for T cells, VISTA acts as a receptor 
on myeloid cells to regulate their activation.
viSTA Negatively Regulates Anti-Tumor 
immunity
VISTA is highly expressed on tumor-infiltrating leukocytes. 
Importantly, it is overexpressed on MDSCs and Tregs, suggest-
ing that VISTA plays a role in tumor evasion from the immune 
system (165). Indeed, VISTA-deficient mice present elevated 
tumor-specific immune response and are more responsive to 
immunization against tumor antigens (163) as well as radio-
therapy treatment (161). However, VISTA deficiency alone is not 
sufficient to reduce tumor growth (163).
VISTA blockade also alters the suppressive character of 
the tumor microenvironment, reducing MDSCs, increasing 
DC activation and enhancing the proliferation and the effec-
tor function of tumor-infiltrating CD4 and CD8 T cells. The 
enhanced tumor-specific immunity results in delayed tumor 
growth in multiple tumor models (165). However, as most 
monotherapies, anti-VISTA is not sufficient to lead to complete 
tumor rejection. When combined with a peptide vaccine, VISTA 
blockade shows synergistic efficacy leading to complete tumor 
eradication in an inducible melanoma model (165). In addi-
tion, anti-VISTA and anti-PD-L1 combination therapy leads to 
tumor regression and synergistically increases tumor-specific 
CD8 T cell effector functions in CT26 colon carcinoma model. 
In non-immunogenic tumor models, combination therapy 
synergizes with vaccination or Treg depletion to induce tumor 
rejection (162).
Concluding Remarks
As summarized in Figure 1, these new NCR pathways present 
striking similarities. Most NCRs are induced upon T cell 
activation and terminate or constrain the effector response by 
feedback inhibition. Some are also expressed on the APCs and 
regulate their stimulatory function. Conversely, multiple NCRs 
are expressed on Tregs and Tr1 and promote their differentiation 
and/or suppressive function. Most are also upregulated on dys-
functional T cells in chronic viral infections and cancer. Finally, 
most have multiple binding partners with which interactions are 
bidirectional with regard to signaling, rendering the assignment 
of ligand and receptor ambiguous or irrelevant. However, despite 
those similarities, their functions are mostly non-redundant. 
Therefore, blocking several of these pathways synergize in restor-
ing efficient anti-tumor responses in preclinical models. The 
recently found astounding efficacy of combined anti-CTLA-4 
and anti-PD-1 therapy in advanced melanoma patients argues in 
favor of targeting multiple pathways for future immunotherapeu-
tic approaches (167–169).
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